Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called “pRNA” to exploit the enormous potential of oligonucleotides for treatment of many common diseases. Our goal is to use RNA building blocks to build ideal therapeutic nanotechnologies to address unmet medical needs. This visionary platform has enormous potential to combine into one nanoparticle all possible RNA functionalities including receptor antagonism/activation, cell targeting/delivery and gene knockdown through mechanisms like RNA interference. Kylin will unlock the full potential of RNA for the treatment of disease.

The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC.  Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin’s success. A lean, cross-functional management team is set to effect early stage success.

Founded by pioneers in the field of RNA Nanotechnology, Kylin Therapeutics is building technology that is capabale of unlocking the full potential of RNA as a therapeutic. Multiple, functionally different RNAs can be incorporated deliberately with precise stoichiometries in a way that is designed to seek out and treat diseased tissue. This strategy can be used to design RNA nanoparticles to treat diseases like cancer, infectious diseases, cardiovascular disease, diabetes, and Alzheimer’s disease.

The Company has created a strong intellectual property portfolio encompassing its core technology and products, with multiple patents and patent applications covering composition of matter for its therapeutic RNA products, as well as method of use patents, with the intent of preventing our competitors from using the RNA Nanotechnology to deliver treatment of any disease amenable to this approach.